Corrigendum: Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

[This corrects the article on p. 213 in vol. 4, PMID: 29238708.

Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece.

Background: Nintedanib represents an antifibrotic compound able to slow down disease progression of patients with idiopathic pulmonary fibrosis (IPF).

Objective: To investigate the safety and efficacy of nintedanib in patients with IPF in a real-life setting.

Methods: This was a multicentre, retrospective, observational, real-life study for patients with IPF receiving nintedanib between October 2014 and October 2016.

Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece.

Background: Pirfenidone is an antifibrotic compound able to slow down disease progression in patients with idiopathic pulmonary fibrosis (IPF).

Objective: To investigate the safety and efficacy of pirfenidone in patients with IPF in a real-life setting.

Methods: This was a multicenter, retrospective, real-life, observational study for patients with IPF receiving pirfenidone.